Stock Price, News, Quote and Profile of SQZ BIOTECHNOLOGIES CO(NYSE:SQZ) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SQZ BIOTECHNOLOGIES CO

NYSE:SQZ (7/3/2023, 7:01:56 PM)

After market: 0.4384 +0 (+0.78%)

0.435

+0.16 (+61.11%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap12.83M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-10-30. The firm is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.

Company Info

SQZ BIOTECHNOLOGIES CO

200 Arsenal Yards Blvd, Suite 210

Watertown MASSACHUSETTS 02472

P: 16177588672.0

CEO: Armon Sharei

Employees: 53

Website: https://sqzbiotech.com/

SQZ News

10 months ago - Seeking AlphaSQZ Biotechnologies to be delisted from the NYSE (NYSE:SQZ)

The New York Stock Exchange has begun proceedings to delist SQZ Biotechnologies (SQZ) common stock. Read more here.

10 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start off the week right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

a year ago - Seeking AlphaSQZ Biotechnologies to effect 1-for-10 reverse stock split (NYSE:SQZ)

Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies (SQZ) has approved a 1-for-10 reverse stock split of its common stock, effective...